Tag: Cancer Care

Nobel Laureate Dr. Harold Varmus Joins Faculty at Weill Cornell Medical College

Yesterday, Weill Cornell Medical College announced the appointment of Dr. Harold Varmus, director of the National Cancer Institute (NCI) at the National Institute of Health (NIH) and co-winner of the Nobel Prize as the Lewis Thomas University Professor of Medicine. Dr. Varmus is internationally recognized for his research on retroviruses and the genetic basis of cancer. At WCMC he will continue research on cancer genomes and their application to cancer care with other investigators at the Sandra and Edward Meyer Cancer Center. From the press release:

“This is a remarkable time in cancer research,” Dr. Varmus said. “Technological advances have enabled scientists to conduct comprehensive genomic studies that are revealing detailed portraits of cancer cells, sparking new opportunities to develop next-generation therapies, diagnostics and prevention strategies. I’m excited to join Weill Cornell Medical College and the New York Genome Center as we strive to reduce the burden of cancer and enhance human health in New York and around the world.”

Continue following this blog for further updates about breakthroughs in lymphoma research from the investigators at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College.

 

New Clinical Trial: Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma

The Weill Cornell Lymphoma Program has recently opened a new clinical trial for men and women with mantle cell lymphoma. The study sponsor is Acerta Pharma BV, and the principal investigator at Weill Cornell is Peter Martin, M.D.. For more information about the study, please call Amelyn Rodgriguez, RN at (212) 746-1362 or e-mail Amelyn at amr2017@med.cornell.edu.

Key Eligibility

  • Men and women greater than or equal to 18 years of age
  • Patient has confirmed Mantle Cell Lymphoma (MCL)
  • The disease has relapsed after or been refractory to at least 1 prior therapy for MCL
  • Detailed eligibility reviewed when you contact the study team

Study Details

The purpose of this study is to determine the activity of ACP-196 in subjects with relapsed or refractory MCL as measured by response rate, duration of response, progression-free survival, and time-to-next treatment.

The design and conduct of this study is supported by an understanding of the natural history and current therapies for subjects with lymphoid cancers; knowledge of the activity and safety of the first-generation Btk inhibitor (eg, ibrutinib) in subjects with hematologic cancers; and the available nonclinical and clinical information regarding ACP-196.

This study is a multicenter, open-label, randomized, parallel group study. No placebo will be administered during this study. Twenty subjects, 10 refractory and 10 relapsed, will be enrolled and will take 100 mg of ACP-196 twice per day.

This clinical trial is a Phase 2, multicenter, open-label study. Subjects will be enrolled and will take 100 mg of ACP-196 twice per day (BID) continuously for approximately 14 months. Patients will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects.

Dr. Richard Furman Discusses Role of Transplantation in High-Risk CLL

As part of an expert panel hosted by OncLive, Dr. Richard Furman discussed the role of transplantation in patients with high-risk CLL.

Previous parts of the discussion can be found here.